Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Status:
RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
Key points:
* Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days
* Doctors will monitor liver health through blood tests and ultrasound scans
* The study will check if Gepaktiv helps improve liver function as effectively as standard treatments.
Main measurements:
* Changes in liver enzyme levels (ALT, AST)
* Reduction in liver size
* Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics